Literature DB >> 15020628

Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?

Michele Reni, Andrés J M Ferreri.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15020628     DOI： 10.1200/JCO.2004.99.259

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Authors:  Keishi Makino; Hideo Nakamura; Taku-Ichiro Hide; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

2.  Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.

Authors:  Keishi Makino; Hideo Nakamura; Taku-ichiro Hide; Jun-ichiro Kuroda; Shigetoshi Yano; Jun-ichi Kuratsu
Journal:  Int J Clin Oncol       Date:  2014-04-11       Impact factor: 3.402

3.  Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.

Authors:  Silvia Chiesa; Stefan Hohaus; Lorenzo Falcinelli; Francesco D'Alò; Massimo Fabrizio Martelli; Stefania Manfrida; Francesco Beghella Bartoli; Cesare Colosimo; Vincenzo Valentini; Cynthia Aristei; Mario Balducci
Journal:  Ann Hematol       Date:  2020-08-20       Impact factor: 3.673

4.  Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience.

Authors:  A Silvani; A Salmaggi; M Eoli; E Lamperti; G Broggi; C E Marras; L Fariselli; I Milanesi; A Fiumani; P Gaviani; A Erbetta; A R Giovagnoli; B Pollo; A Botturi; A Boiardi
Journal:  J Neurooncol       Date:  2006-11-17       Impact factor: 4.506

5.  Temozolomide as salvage treatment in primary brain lymphomas.

Authors:  M Reni; F Zaja; W Mason; J Perry; E Mazza; M Spina; R Bordonaro; F Ilariucci; M Faedi; G Corazzelli; P Manno; E Franceschi; A Pace; M Candela; A Abbadessa; C Stelitano; G Latte; A J M Ferreri
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.